CN Patent

CN111164085B — 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途

Assigned to Hangzhou Lingye Pharmaceutical Technology Co ltd · Expires 2023-04-04 · 3y expired

What this patent protects

本发明涉及瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶，包括瑞博西林和糖精的共晶、瑞博西林和胆酸的共晶、瑞博西林和乳清酸的共晶以及瑞博西林单琥珀酸盐和柠檬酸的共晶，与现有技术相比，所述共晶具有一种或多种改进的特性。本发明还涉及瑞博西林和糖精的共晶、瑞博西林和胆酸的共晶、瑞博西林和乳清酸的共晶以及瑞博西林单琥珀酸盐和柠檬酸的共晶的制备方法，其药物组合物及其用于制备治疗和/或预防涉及蛋白激酶相关障碍、癌症、移植排除和自身免疫疾病的一种或多种症状等疾病的药物中的用途。

USPTO Abstract

本发明涉及瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶，包括瑞博西林和糖精的共晶、瑞博西林和胆酸的共晶、瑞博西林和乳清酸的共晶以及瑞博西林单琥珀酸盐和柠檬酸的共晶，与现有技术相比，所述共晶具有一种或多种改进的特性。本发明还涉及瑞博西林和糖精的共晶、瑞博西林和胆酸的共晶、瑞博西林和乳清酸的共晶以及瑞博西林单琥珀酸盐和柠檬酸的共晶的制备方法，其药物组合物及其用于制备治疗和/或预防涉及蛋白激酶相关障碍、癌症、移植排除和自身免疫疾病的一种或多种症状等疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN111164085B
Jurisdiction: CN
Classification: —
Expires: 2023-04-04
Drug substance claim: No
Drug product claim: No
Assignee: Hangzhou Lingye Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.